Structures of ceftazidime and its transition-state analogue in complex with AmpC β-lactamase:: Implications for resistance mutations and inhibitor design

Third-generation cephalosporins are widely used beta -lactam antibiotics that resist hydrolysis by beta -lactamases. Recently, mutant beta -lactamases that rapidly inactivate these drugs have emerged. To investigate why third-generation cephalosporins are relatively stable to wild-type class C beta -lactamases and how mutant enzymes might overcome this, the structures of the class C beta -lactamase AmpC in complex with the third-generation cephalosporin ceftazidime and with a transition-state analogue of ceftazidime were determined by X-ray crystallography to 2.0 and 2.3 Angstrom resolution, respectively. Comparison of the acyl-enzyme structures of ceftazidime and loracarbef, a beta -lactam substrate, reveals that the conformation of ceftazidime in the active site differs from that of substrates. Comparison of the structures of the acyl-enzyme intermediate and the transition-state analogue suggests that ceftazidime blocks formation of the tetrahedral transition state, explaining why it is an inhibitor of AmpC. Ceftazidime cannot adopt a conformation competent for catalysis due to steric clashes that would occur with conserved residues Val211 and Tyr221. The X-ray crystal structure of the mutant beta -lactamase GC1, which has improved activity against third-generation cephalosporins, suggests that a tandem tripeptide insertion in the Omega loop, which contains Val211, has caused a shift of this residue and also of Tyr221 that would allow ceftazidime and other third-generation cephalosporins to adopt a more catalytically competent conformation. These structural differences may explain the extended spectrum activity of GC1 against this class of cephalosporins. In addition, the complexed structure of the transition-state analogue inhibitor (K-i 20 nM) with AmpC reveals potential opportunities for further inhibitor design.